Design and analytical validation of clinical DNA sequencing assays

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 1, 2012, Pages 41-46

  Pont Kingdon, Genevieve ^a   Gedge, Friederike ^a   Wooderchak Donahue, Whitney ^a   Schrijver, Iris ^b   Weck, Karen E ^c   Kant, Jeffrey A ^d   Oglesbee, Devin ^e   Bayrak Toydemir, Pinar ^a,f   Lyon, Elaine ^f,g  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE; RAD53 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN; SMAD4 PROTEIN;

ARTICLE; CONGENITAL TUMOR; DNA SEQUENCE; FOOD AND DRUG ADMINISTRATION; GENETICS; HUMAN; METHODOLOGY; MOLECULAR DIAGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; UNITED STATES;

CELL CYCLE PROTEINS; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; SACCHAROMYCES CEREVISIAE PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SMAD4 PROTEIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856035237     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0623-OA     Document Type: Article

References (11)

1. Zoccoli MA, Chan M, Erker JC, Ferreira-Gonzalez A, Lubin IM. Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicin; Approved Guideline. NCCLS document MM9-A. Wayne, PA: NCCLS; 2004.
2. Association for Molecular Pathology. Association for Molecular Pathology statement: recommendations for in-house development and operation of molecular diagnostic tests. Am J Clin Pathol. 1999;111(4):449-463.
3. Strom CM, Huang D, Chen C, et al. Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test. Genet Med. 2003;5(1):9-14. (Pubitemid 41184271)
4. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-386.
5. Calderon FR, Phansalkar AR, Crockett DK, Miller M, Mao R. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum Mutat. 2007;28(10):939-943. (Pubitemid 47519385)
6. Crockett DK, Pont-Kingdon G, Gedge F, Sumner K, Seamons R, Lyon E. The Alport syndrome COL4A5 variant database. Hum Mutat. 2010;31(8):E1652-E1657.
7. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008;10(4):294-300. (Pubitemid 351544132)
8. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425-432.
9. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred: I, accuracy assessment. Genome Res. 1998;8(3):175-185. (Pubitemid 28177229)
10. Ewing B, Green P. Base-calling of automated sequencer traces using phred: II, error probabilities. Genome Res. 1998;8(3):186-194. (Pubitemid 28177230)
11. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131(6):852-863. (Pubitemid 46906376)